Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK). DermNet NZ Editor in Chief: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, January 2018
Guselkumab is a biologic treatment indicated for moderate to severe psoriasis.
The U.S. Food and Drug Administration (FDA) has approved guselkumab (Janssen Biotech, PA, USA; TREMFYA™) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Guselkumab is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis.
Applications seeking approval of guselkumab in the European Union, Japan and other countries are currently under review.
The most common adverse reactions (≥ 1% of patients) reported include:
Guzelkumab should not be used in patients that:
Guselkumab is promising for plaque psoriasis in phase 3 studies.
See the DermNet NZ bookstore.
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.